HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Adverse Events Spark FDA Evaluation Of Topical Acne Ingredients

This article was originally published in The Rose Sheet

Executive Summary

A recent uptick in the number of adverse events reported for benzoyl peroxide and salicylic acid products has pushed the regulatory agency to take a closer look at the potential for safety issues.

Advertisement

Related Content

OTC Acne Treatment Labels Should Add Sensitivity Test Direction – FDA
Natural OTCs Sprout From Firms’ Innovations Within Monograph Limits
Natural OTCs Sprout From Firms’ Innovations Within Monograph Limits
Natural OTCs Sprout From Firms’ Innovations Within Monograph Limits
Natural OTCs Sprout From Firms’ Innovations Within Monograph Limits
OTC Firms Should Improve Monograph Compliance, Registration – CDER
Return To Sender, Industry Groups Say Of AER Address Guidance

Related Companies

Advertisement
UsernamePublicRestriction

Register

RS019377

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel